Ikena Oncology Inc (IKNA) News

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a...

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted...

Form 8-K - Current report

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in...

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted...